Organic Coatings Patents (Class 424/475)
  • Patent number: 10010620
    Abstract: A process for the preparation of an erodible tamper-resistant dosage form that comprises a therapeutic agent-substrate complex embedded in a thermo-formable matrix, such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive. The dosage form provides resistance to intentional or unintentional tampering such as chewing, crushing and grinding, and volatilization.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: July 3, 2018
    Assignee: ExxPharma Therapeutics LLC
    Inventors: Isaac Ghebre-Sellassie, Hibreniguss Terefe
  • Patent number: 9993435
    Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 12, 2018
    Assignee: UNIVERSITY COLLEGE LONDON
    Inventors: Abdul Waseh Basit, Valentine Chidi Ibekwe
  • Patent number: 9949964
    Abstract: The present invention relates to tesofensine compositions, methods to prepare the same and uses thereof in preparing medicines for the prevention and treatment of overweight, obesity and type 2 diabetes mellitus.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 24, 2018
    Assignee: Saniona A/S
    Inventor: Bruno Racheboeuf
  • Patent number: 9295652
    Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: March 29, 2016
    Assignee: Mayne Pharma International Pty. Ltd.
    Inventors: Stefan Lukas, Angelo Lepore, Stuart Mudge
  • Publication number: 20150132378
    Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 14, 2015
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Murali Krishna Bhavarisetti, Kumaravel Vivek, Sreekanth Narravula, Romi Barat Singh
  • Publication number: 20150118305
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and ursolic acid, a salt, ester, amide, or derivative thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and ursolic acid, a salt, ester, amide, or derivative thereof. The invention also relates to the combination of a broccoli extract or powder and ursolic acid, a salt, ester, amide, or derivative thereof. The invention provides compositions and methods relating to these combinations.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Publication number: 20150118306
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Brian CORNBLATT, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 8980320
    Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Ryoji Yoshii, Yuki Hayashi, Yuki Fujisaki
  • Publication number: 20150056281
    Abstract: This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-?. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-? for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-? in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-? in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 26, 2015
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Yossi Gilgun, Nora Tarcic
  • Patent number: 8962018
    Abstract: The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: February 24, 2015
    Assignee: Laboratorios Lesvi, S.L.
    Inventors: Ignacio Diez Martin, Carmen Ubeda Perez, Pablo Pablo Alba
  • Publication number: 20150050335
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Application
    Filed: February 28, 2013
    Publication date: February 19, 2015
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Publication number: 20150037407
    Abstract: A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy of the pharmaceutical product.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 5, 2015
    Inventors: Rebanta Bandyopadhyay, Susen Werle
  • Publication number: 20140370086
    Abstract: Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and/or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and/or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 18, 2014
    Inventors: Ziv Harish, Russ Weinzimmer
  • Patent number: 8900606
    Abstract: A method improves stability of drugs in a solid pharmaceutical formulation against oxygen and water vapor by coating the solid pharmaceutical formulation with a coating material including a high hydrogen-bonding resin and a swelling clay.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 2, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Yuki Hayashi, Yuki Fujisaki, Ryoji Yoshii
  • Patent number: 8871264
    Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: October 28, 2014
    Assignee: AstraZeneca AB
    Inventors: Agneta Hallgren, Ralf Magnus Werner Swenson
  • Publication number: 20140294958
    Abstract: The present invention relates to lubricious coatings comprising an ionomer and a hydrophilic polymer wherein the ionomer is cross-linked using a suitable cross-linking agent, and optionally also conventional excipients, such as a surfactant, a plasticizer and/or a filler. The invention also relates to pharmaceutical products covered by such lubricious coatings, compositions for preparing these lubricious coatings and a method for providing pharmaceutical products with these lubricious coatings.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 2, 2014
    Inventors: Johannes Wilhelmus Belt, Yogesh Nathalal Gandhi
  • Patent number: 8846087
    Abstract: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: September 30, 2014
    Assignee: Sensient Colors LLC
    Inventor: Vic Young
  • Publication number: 20140271857
    Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 18, 2014
    Applicant: TRIS Pharma Inc.
    Inventors: Andrea Nelson, Quin-Zene Chen, Harsh Mehta, Yu-Hsing Tu
  • Publication number: 20140248350
    Abstract: The present invention includes pH dependent, dry film coating compositions containing calcium silicate for use on orally-ingestible substrates such as tablets and the like. The film coating compositions can be applied as an aqueous suspension either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either an enteric or reverse-enteric polymer. Methods of preparing the dry film coatings, methods of preparing corresponding aqueous suspensions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 4, 2014
    Applicant: BPSI Holdings, LLC.
    Inventors: George REYES, Charles R. CUNNINGHAM, Thomas P. FARRELL, Cara YOUNG
  • Publication number: 20140227358
    Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Michael AMBUHL, Jutta BEYER, Begona CARRENO-GOMEZ, Colleen RUEGGER, Stephen VALAZZA
  • Publication number: 20140178311
    Abstract: A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within each subsequent dose of the medicine, the amount of the APA decreases and the amount of the ABA increases, or remains the same, or decreases relative to an earlier amount. A trace of the APA may or may not remain in the pill toward the end of medicine application.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 26, 2014
    Inventors: Joshua D. Levine, Robert A. Levine
  • Publication number: 20140127295
    Abstract: The present disclosure describes a composition and a kit having a plurality of compounds for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA). The disclosure also relates to a process of obtaining the composition and the method of treating diseases by administration of the compositions.
    Type: Application
    Filed: March 7, 2012
    Publication date: May 8, 2014
    Applicants: Cellworks Group, Inc, Cellworks Research India Private Limited
    Inventors: Shireen Vali, Robinson Vidva, Prashant Ramachandran Nair, Pradeep Fernandes, Taher Abbasi, Saumya Radhakrishnan
  • Publication number: 20140127299
    Abstract: Disclosed herein are food-grade enteric coating compositions designed to release pharmaceutical and/or nutraceutical products at various regions of the intestines, wherein said compositions comprise a film former and a pore former. Also disclosed herein are methods of making and using same.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 8, 2014
    Inventor: Stephen Kwaku Dordunoo
  • Publication number: 20140112988
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 24, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Patent number: 8697126
    Abstract: The present invention describes a process for the manufacture of a solid composition comprising a microorganism, which process comprises a first step of blending and/or compacting the microorganism with a salt of a medium or long-chain fatty acid to prepare a powderous mixture or compacted granulate, and a second step of providing said powderous mixture or compacted granulate with a coating. The microorganisms are preferably probiotics. The invention also relates to the solid composition obtained by said process and to its use in food.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: April 15, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Chyi-Cheng Chen, Bruno H. Leuenberger, Loni Schweikert, Ernst Zedi
  • Patent number: 8684739
    Abstract: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network of pores and slowly released by internal flow, and wherein the network of pores is substantially non-collapsible upon removal of the active ingredient. The porous co-polymer bead preparation comprises a continuous aqueous phase solution containing a monomeric mixture of at least one polyvinylaromatic monomer and at least one porogen forming a network that comprising (i) macropores; (ii) mesopores; (iii) micropores; and (iv) gel porosity. Also provided are methods of preparing the porous co-polymer bead preparation; and for its use as a slow-release delivery vehicle.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: April 1, 2014
    Assignee: Mycone Dental Supply Co., Inc.
    Inventors: Larry W. Steffier, David Kurz, Robert R. Raney, Cary B. Robinson
  • Patent number: 8685452
    Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: April 1, 2014
    Assignee: Lek Pharmaceuticals D.D.
    Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
  • Patent number: 8679534
    Abstract: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: March 25, 2014
    Assignee: Andrx Labs, LLC
    Inventors: Chih-Ming Chen, Joseph Chou, David Wong
  • Publication number: 20140079778
    Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf-life storage.
    Type: Application
    Filed: January 31, 2012
    Publication date: March 20, 2014
    Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb Company
    Inventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
  • Patent number: 8673353
    Abstract: The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: March 18, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd
    Inventors: Makiko Yanagida, Hiroyuki Nishii, Masayuki Nakazono
  • Patent number: 8647645
    Abstract: The present invention is directed to immediate release film coating systems for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which have improved moisture barrier properties. The film coating systems can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the moisture barrier film coating is prepared as a dry powder mixture containing polyvinyl alcohol, a polymer with pH dependent solubility, a plasticizer, a glidant, and, optionally, a detackifier, an alkalizing agent and a pigment. Film coating compositions containing an aqueous suspension of the powder mixtures, methods of applying the coatings to substrates and the coated substrates are also disclosed.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: February 11, 2014
    Assignee: BPSI Holdings, LLC
    Inventors: Thomas P. Farrell, Jason Teckoe
  • Publication number: 20140023710
    Abstract: The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described.
    Type: Application
    Filed: September 16, 2013
    Publication date: January 23, 2014
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Mahendra G. Dedhiya, Anil Chhettry, Yan Yang, Yun Mo, Bhaveshkumar H. Kothari
  • Patent number: 8632808
    Abstract: A solid preparation sufficiently masking the unpleasant taste of pioglitazone or a salt thereof; a solid preparation sufficiently masking the unpleasant taste of pioglitazone or a salt thereof and having superior properties of superior disintegration property in the oral cavity, appropriate preparation strength, long-term preservation stability and the like is provided. The present invention provides a solid preparation comprising particles comprising (i) core particles comprising an excipient, and (ii) pioglitazone or a salt thereof and an acid-soluble polymer both coating the core particles.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: January 21, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuhiro Okochi, Arisa Maeda
  • Patent number: 8609198
    Abstract: A method for producing a pharmaceutical dose form includes depositing a measured quantity of a first coating material on an external surface of the dose form in a patterned configuration. A measured quantity of a second coating material is deposited on the surface of the dose form in a patterned configuration in relationship to the first coating material. The first and second coating materials form a coating layer in overlying relationship with at least a portion of the external surface of the dose form.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: December 17, 2013
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Iddys D. Figueroa, Enrique C. Abreu
  • Publication number: 20130330406
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Application
    Filed: August 13, 2013
    Publication date: December 12, 2013
    Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb Company
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Patent number: 8591948
    Abstract: The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: November 26, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Lieven Elvire Colette Baert, Geert Verreck, Dany Thoné
  • Publication number: 20130309302
    Abstract: The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 21, 2013
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Bayer Pharma Aktiengesellschaft
  • Patent number: 8551524
    Abstract: A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor and a slow release biguanide is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide is also provided.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: October 8, 2013
    Assignee: IYCUS, LLC
    Inventor: Ramesh Sesha
  • Publication number: 20130243857
    Abstract: The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 19, 2013
    Applicant: JANSSEN R & D IRELAND
    Inventors: Reza Oliyai, Lauren Wiser, Mark Menning
  • Patent number: 8524277
    Abstract: A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: September 3, 2013
    Assignee: Alza Corporation
    Inventors: David E. Edgren, Patrick S.-L. Wong, Gurdish K. Bhatti, Shu Li, Robert R. Skluzacek
  • Publication number: 20130216619
    Abstract: The present invention relates to an oral pharmaceutical composition comprising: a) a core comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent; b) an intermediate coating over the core; and c) an outer coating comprising ezetimibe.
    Type: Application
    Filed: February 13, 2013
    Publication date: August 22, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventor: Ranbaxy Laboratories Limited
  • Publication number: 20130122093
    Abstract: The invention relates to pharmaceutical compositions of ?N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders
    Type: Application
    Filed: January 7, 2013
    Publication date: May 16, 2013
    Inventors: Julia ZH Gao, Rajeshwar Motheram
  • Publication number: 20130115286
    Abstract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 9, 2013
    Inventors: Mario Brufani, Bianca Maria Lagrasta, Rolando Marzella, Ilaria Medici, Silvio Silvestri
  • Patent number: 8431157
    Abstract: The invention relates to a partly neutralized anionic (meth)acrylate copolymer consisting of radically polymerized units containing 25-95% by weight (meth)acrylic acid C1 to C4 alkylesters and 5-75% by weight (meth)acrylate monomer with an anionic group, wherein 0.1 to 25% contained anionic groups are neutralized by a base. Said invention is characterized in that said base is embodied in the form of an cationic organic base whose molecular weight is greater than 150. A medical form containing said partly neutralized anionic (meth)acrylate copolymer and the use of said partly neutralized anionic (meth)acrylate copolymer for producing a medical form rapidly releasing an active substance having a determined pH value are also disclosed.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: April 30, 2013
    Assignee: Evonik Roehm GmbH
    Inventors: Rosario Lizio, Hans-Ulrich Petereit, Erna Roth, Michael Damm, Ruediger Alexowsky
  • Patent number: 8399016
    Abstract: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm?2 at a solid fraction representative of the tablet.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 19, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gregory Everett Amidon, Loksidh Devi Ganorkar, John Mark Heimlich, Ernest J. Lee, Robert Martin Noack, Joseph Peter Reo, Connie Jo Skoug
  • Publication number: 20130034606
    Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.
    Type: Application
    Filed: November 12, 2010
    Publication date: February 7, 2013
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Agneta Hallgren, Ralf Magnus Werner Swenson
  • Patent number: 8367104
    Abstract: A pharmaceutical composition for oral administration comprising a core and a film coating on the core that exhibits enhanced disintegration characteristics is disclosed. The film coating comprises a film forming polymer, an organic solvent, a super-disintegrant and, optionally, an acid labile material.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: February 5, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Jen-Chi Chen, Frank J. Bunick, Gerard McNally
  • Patent number: 8313768
    Abstract: In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape including a powder blend containing a pharmaceutically active agent and a thermally-sensitive material; and (b) applying energy in different amounts to different regions of the tablet shape to form the tablet in a manner such that: (i) a first region of the tablet shape is exposed to said energy for a sufficient period of time to melt the thermally-sensitive material within the first region to form said modified release region of said tablet; and (ii) a second region of said tablet shape is not so exposed to the energy such that said second region forms the immediate release region of said tablet.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: November 20, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Leo B. Kriksunov, Harry S. Sowden, Joseph R. Luber, Frank J. Bunick
  • Publication number: 20120288559
    Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 15, 2012
    Inventors: Michael Ambühl, Jutta Beyer, Begona Carreno-Gomez, Colleen Ruegger, Stephen Valazza
  • Patent number: 8293273
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: October 23, 2012
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati